NO327080B1 - Syntetisk opioidpeptidamid samt et farmasoytisk preparat - Google Patents

Syntetisk opioidpeptidamid samt et farmasoytisk preparat Download PDF

Info

Publication number: NO327080B1
Authority: NO; Norway
Prior art keywords: phe; arg; nle; peptide; xaa2
Prior art date: 1997-12-23

Application number

NO20003245A

Other languages

English (en)

Norwegian (no)

Other versions

NO20003245L (no

NO20003245D0 (no

Inventor

Claudio D Schteingart

Jean-Louis Junien

Pierre J M Riviere

Javier Sueiras Diaz

Jerzy A Trojnar

Todd W Vanderah

Original Assignee

Cara Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-23

Filing date

2000-06-21

Publication date

2009-04-20

2000-06-21 Application filed by Cara Therapeutics Inc filed Critical Cara Therapeutics Inc

2000-06-21 Publication of NO20003245D0 publication Critical patent/NO20003245D0/no

2000-08-23 Publication of NO20003245L publication Critical patent/NO20003245L/no

2009-04-20 Publication of NO327080B1 publication Critical patent/NO327080B1/no

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 claims description 60
-1 D-1Nal Chemical compound 0.000 claims description 56
108010093625 Opioid Peptides Proteins 0.000 claims description 33
102000001490 Opioid Peptides Human genes 0.000 claims description 33
239000003399 opiate peptide Substances 0.000 claims description 33
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 27
230000003502 anti-nociceptive effect Effects 0.000 claims description 27
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 19
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 15
150000001408 amides Chemical class 0.000 claims description 15
AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 12
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 12
JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims description 10
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 10
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 8
FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 8
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
125000004193 piperazinyl group Chemical group 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
125000001544 thienyl group Chemical group 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
125000002757 morpholinyl group Chemical group 0.000 claims description 5
125000004568 thiomorpholinyl group Chemical group 0.000 claims description 5
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 4
FXHCFPUEIDRTMR-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;chloride Chemical compound Cl.C1=CC=C2CNC(C(=O)O)CC2=C1 FXHCFPUEIDRTMR-UHFFFAOYSA-N 0.000 claims description 4
125000003386 piperidinyl group Chemical group 0.000 claims description 4
YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 claims description 3
125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
108020001588 κ-opioid receptors Proteins 0.000 description 37
238000012360 testing method Methods 0.000 description 27
102100031819 Kappa-type opioid receptor Human genes 0.000 description 26
102000004196 processed proteins & peptides Human genes 0.000 description 25
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
150000001875 compounds Chemical class 0.000 description 20
210000004556 brain Anatomy 0.000 description 19
230000000694 effects Effects 0.000 description 18
238000001727 in vivo Methods 0.000 description 17
239000000243 solution Substances 0.000 description 14
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
108020001612 μ-opioid receptors Proteins 0.000 description 12
230000009471 action Effects 0.000 description 11
102000048260 kappa Opioid Receptors Human genes 0.000 description 11
239000000556 agonist Substances 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
239000003446 ligand Substances 0.000 description 9
238000000034 method Methods 0.000 description 9
230000002093 peripheral effect Effects 0.000 description 9
230000035515 penetration Effects 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
230000027455 binding Effects 0.000 description 6
125000006239 protecting group Chemical group 0.000 description 6
239000002287 radioligand Substances 0.000 description 6
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
239000002253 acid Substances 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
229940035676 analgesics Drugs 0.000 description 5
239000000730 antalgic agent Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
208000022559 Inflammatory bowel disease Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
230000000202 analgesic effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
101000992298 Homo sapiens Kappa-type opioid receptor Proteins 0.000 description 3
206010029260 Neuroblastoma Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000000971 hippocampal effect Effects 0.000 description 3
102000043672 human OPRK1 Human genes 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
208000002551 irritable bowel syndrome Diseases 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
230000036407 pain Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000009278 visceral effect Effects 0.000 description 3
208000009935 visceral pain Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 2
101100449952 Arabidopsis thaliana KOR gene Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
206010013954 Dysphoria Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020853 Hypertonic bladder Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
208000004880 Polyuria Diseases 0.000 description 2
208000004550 Postoperative Pain Diseases 0.000 description 2
208000004756 Respiratory Insufficiency Diseases 0.000 description 2
206010038678 Respiratory depression Diseases 0.000 description 2
206010039897 Sedation Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
230000003385 bacteriostatic effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
230000035619 diuresis Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
238000007654 immersion Methods 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
102000051367 mu Opioid Receptors Human genes 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
101150009274 nhr-1 gene Proteins 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000036280 sedation Effects 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
UJOQOPBFLFQOJJ-HXUWFJFHSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-methylhexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UJOQOPBFLFQOJJ-HXUWFJFHSA-N 0.000 description 1
IFPQOXNWLSRZKX-GSVOUGTGSA-N (2r)-2-amino-4-(diaminomethylideneamino)butanoic acid Chemical compound OC(=O)[C@H](N)CCNC(N)=N IFPQOXNWLSRZKX-GSVOUGTGSA-N 0.000 description 1
QUOGESRFPZDMMT-RXMQYKEDSA-N (2r)-2-amino-6-(diaminomethylideneamino)hexanoic acid Chemical group OC(=O)[C@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-RXMQYKEDSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
JMBYBVLCYODBJQ-HFMPRLQTSA-N 2-(1-benzofuran-4-yl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=3C=COC=3C=CC=2)C[C@]21CCCO2 JMBYBVLCYODBJQ-HFMPRLQTSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical group CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
BWKMGYQJPOAASG-SECBINFHSA-N D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-SECBINFHSA-N 0.000 description 1
AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
150000008541 D-alanines Chemical group 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000836173 Homo sapiens Tumor protein p53-inducible nuclear protein 2 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
229940127450 Opioid Agonists Drugs 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102400000096 Substance P Human genes 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
206010060926 abdominal symptom Diseases 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
108700023159 delta Opioid Receptors Proteins 0.000 description 1
102000048124 delta Opioid Receptors Human genes 0.000 description 1
238000011161 development Methods 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
229950010961 enadoline Drugs 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000008384 ileus Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005040 ion trap Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
239000002632 kappa opiate receptor agonist Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960005010 orotic acid Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920006122 polyamide resin Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
150000003140 primary amides Chemical class 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20003245A 1997-12-23 2000-06-21 Syntetisk opioidpeptidamid samt et farmasoytisk preparat NO327080B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/997,208 US5965701A (en)	1997-12-23	1997-12-23	Kappa receptor opioid peptides
PCT/US1998/027282 WO1999032510A1 (fr)	1997-12-23	1998-12-22	Peptides recepteurs opioides kappa

Publications (3)

Publication Number	Publication Date
NO20003245D0 NO20003245D0 (no)	2000-06-21
NO20003245L NO20003245L (no)	2000-08-23
NO327080B1 true NO327080B1 (no)	2009-04-20

Family

ID=25543752

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20003245A NO327080B1 (no)	1997-12-23	2000-06-21	Syntetisk opioidpeptidamid samt et farmasoytisk preparat

Country Status (32)

Country	Link
US (1)	US5965701A (fr)
EP (1)	EP1042359B1 (fr)
JP (1)	JP4275852B2 (fr)
KR (1)	KR100629548B1 (fr)
CN (1)	CN1154655C (fr)
AR (1)	AR014167A1 (fr)
AT (1)	ATE301670T1 (fr)
AU (1)	AU747806B2 (fr)
BR (2)	BR9814499B1 (fr)
CA (1)	CA2315878C (fr)
CR (1)	CR5936A (fr)
CZ (1)	CZ297281B6 (fr)
DE (1)	DE69831176T2 (fr)
DK (1)	DK1042359T3 (fr)
EE (1)	EE04440B1 (fr)
ES (1)	ES2247735T3 (fr)
HR (1)	HRP20000415B1 (fr)
HU (1)	HU227640B1 (fr)
IL (3)	IL136742A0 (fr)
MY (1)	MY117542A (fr)
NO (1)	NO327080B1 (fr)
NZ (1)	NZ505183A (fr)
PL (1)	PL195842B1 (fr)
PT (1)	PT1042359E (fr)
RU (1)	RU2217437C2 (fr)
SK (1)	SK286135B6 (fr)
TR (1)	TR200001985T2 (fr)
TW (1)	TW580502B (fr)
UA (1)	UA68366C2 (fr)
UY (1)	UY25327A1 (fr)
WO (1)	WO1999032510A1 (fr)
ZA (1)	ZA9811801B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
AU1623801A (en) *	1999-11-19	2001-05-30	Palatin Technologies, Inc.	Opioid metallopeptide compositions and methods
DE10116978A1 (de)	2001-04-05	2002-10-10	Merck Patent Gmbh	Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
JP4239592B2 (ja) *	2001-05-08	2009-03-18	東レ株式会社	敗血症治療剤
ATE385193T1 (de)	2002-03-20	2008-02-15	Mannkind Corp	Inhalationsgerät
DE602005024413D1 (de)	2004-08-20	2010-12-09	Mannkind Corp	Katalyse der diketopiperazinsynthese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
JP5167133B2 (ja)	2005-09-14	2013-03-21	マンカインドコーポレイション	結晶性微粒子表面に対する活性薬剤の親和性の増大に基づく薬物処方の方法
MX2008010721A (es)	2006-02-22	2008-09-01	Mannkind Corp	Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
CA2653072A1 (fr) *	2006-05-26	2007-12-06	Cara Therapeutics, Inc.	Procede destine a elever le taux de prolactine chez des mammiferes
JP2009538316A (ja) *	2006-05-26	2009-11-05	カラセラピューティクスインコーポレイテッド	κオピオイド受容体ペプチドのＮ−オキシド
US7842662B2 (en) *	2006-11-10	2010-11-30	Cara Therapeutics, Inc.	Synthetic peptide amide dimers
US7713937B2 (en) *	2006-11-10	2010-05-11	Cara Therapeutics, Inc.	Synthetic peptide amides and dimeric forms thereof
CN101627049B (zh)	2006-11-10	2012-09-05	卡拉治疗学股份有限公司	合成酞酰胺
US8906859B2 (en) *	2006-11-10	2014-12-09	Cera Therapeutics, Inc.	Uses of kappa opioid synthetic peptide amides
US8236766B2 (en) *	2006-11-10	2012-08-07	Cara Therapeutics, Inc.	Uses of synthetic peptide amides
WO2008077194A1 (fr) *	2006-12-22	2008-07-03	Xenome Ltd	Agonistes de récepteurs
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
JP5421362B2 (ja)	2008-06-13	2014-02-19	マンカインドコーポレイション	薬物送達用の乾燥粉末吸入器およびシステム
RU2470681C2 (ru)	2008-06-20	2012-12-27	Маннкайнд Корпорейшн	Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (fr)	2009-03-11	2013-11-06	MannKind Corporation	Appareil, système et procédé de mesure de résistance d'un inhalateur
US8551528B2 (en)	2009-06-12	2013-10-08	Mannkind Corporation	Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (fr)	2009-11-03	2012-09-12	MannKind Corporation	Appareil et méthode de simulation d'efforts d'inhalation
JP6385673B2 (ja)	2010-06-21	2018-09-05	マンカインドコーポレイション	乾燥粉末薬物送達システム
WO2012135765A2 (fr)	2011-04-01	2012-10-04	Mannkind Corporation	Emballage coque pour cartouches pharmaceutiques
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
IN2014DN03093A (fr) *	2011-10-24	2015-05-15	Mannkind Corp
AU2013289957B2 (en)	2012-07-12	2017-02-23	Mannkind Corporation	Dry powder drug delivery systems and methods
WO2014066856A1 (fr)	2012-10-26	2014-05-01	Mannkind Corporation	Compositions et procédés de vaccin antigrippal inhalable
ES2754388T3 (es)	2013-03-15	2020-04-17	Mannkind Corp	Composiciones y métodos de dicetopiperazina microcristalina
AU2014290438B2 (en)	2013-07-18	2019-11-07	Mannkind Corporation	Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (ja)	2013-08-05	2016-10-06	マンカインドコーポレイション	通気装置及び方法
WO2015148905A1 (fr)	2014-03-28	2015-10-01	Mannkind Corporation	Utilisation d'insuline à action ultrarapide
KR102303092B1 (ko) *	2014-06-26	2021-09-15	마루이시세이야쿠가부시키가이샤	합성 펜타펩티드의 제조법
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EP3294315A2 (fr)	2015-05-11	2018-03-21	Cadila Healthcare Limited	Nouveaux peptides à chaîne courte en tant qu'agonistes des récepteurs opioïdes kappa (kor)
CN107098876B (zh) *	2016-02-23	2021-04-06	江苏恒瑞医药股份有限公司	苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
WO2018059331A1 (fr) *	2016-09-27	2018-04-05	四川科伦博泰生物医药股份有限公司	Composé polyamide et son utilisation
CA3069820C (fr) *	2017-07-21	2022-12-06	Sichuan Haisco Pharmaceutical Co., Ltd.	Composes d'amide peptidique, son procede de fabrication et application medicale
KR20200096588A (ko)	2017-12-06	2020-08-12	지앙수 헨그루이 메디슨 컴퍼니 리미티드	페닐프로피온아마이드 유도체의 염 및 이의 제조 방법
RU2768482C1 (ru)	2018-05-16	2022-03-24	Цзянсу Хэнжуй Медсин Ко., Лтд.	Фармацевтическая композиция агониста каппа-опиоидного рецептора
WO2021013085A1 (fr) *	2019-07-25	2021-01-28	四川海思科制药有限公司	Sel d'amide peptidique, son procédé de préparation et son utilisation en médecine
WO2021013086A1 (fr) *	2019-07-25	2021-01-28	四川海思科制药有限公司	Composé d'amide de peptide deutéré, son procédé de préparation et son application en médecine
CN114615976A (zh) *	2019-08-07	2022-06-10	人福医药美国公司	κ阿片受体肽酰胺激动剂
EP4175944A4 (fr)	2020-06-25	2024-03-06	Humanwell Pharmaceutical US	Peptides pour le traitement de troubles médicaux
US20240336565A1 (en)	2021-07-02	2024-10-10	Acer Therapeutics, Inc.	Solid forms of osanetant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2013689B (en) *	1977-12-15	1982-03-24	Reckitt & Colmann Prod Ltd	Compounds
GB8801304D0 (en) *	1988-01-21	1988-02-17	Ici Plc	Diamine compounds
US5367053A (en) *	1993-05-19	1994-11-22	Houghten Pharmaceuticals, Inc.	Opioid peptide inhibitors
RU2067000C1 (ru) *	1994-06-29	1996-09-27	Владислав Исакович Дейгин	Пептид и способ его получения
US5610271A (en) *	1995-06-07	1997-03-11	Torrey Pines Institute For Molecular Studies	Kappa receptor selective opioid peptides

1997
- 1997-12-23 US US08/997,208 patent/US5965701A/en not_active Expired - Lifetime
1998
- 1998-12-22 HU HU0100626A patent/HU227640B1/hu not_active IP Right Cessation
- 1998-12-22 AT AT98964224T patent/ATE301670T1/de active
- 1998-12-22 DK DK98964224T patent/DK1042359T3/da active
- 1998-12-22 PL PL98341308A patent/PL195842B1/pl not_active IP Right Cessation
- 1998-12-22 MY MYPI98005818A patent/MY117542A/en unknown
- 1998-12-22 IL IL13674298A patent/IL136742A0/xx active IP Right Grant
- 1998-12-22 EE EEP200000370A patent/EE04440B1/xx not_active IP Right Cessation
- 1998-12-22 PT PT98964224T patent/PT1042359E/pt unknown
- 1998-12-22 ES ES98964224T patent/ES2247735T3/es not_active Expired - Lifetime
- 1998-12-22 CR CR5936A patent/CR5936A/es unknown
- 1998-12-22 TR TR2000/01985T patent/TR200001985T2/xx unknown
- 1998-12-22 DE DE69831176T patent/DE69831176T2/de not_active Expired - Lifetime
- 1998-12-22 HR HR20000415A patent/HRP20000415B1/xx not_active IP Right Cessation
- 1998-12-22 CA CA2315878A patent/CA2315878C/fr not_active Expired - Lifetime
- 1998-12-22 BR BRPI9814499-5A patent/BR9814499B1/pt not_active IP Right Cessation
- 1998-12-22 CZ CZ20002382A patent/CZ297281B6/cs not_active IP Right Cessation
- 1998-12-22 RU RU2000119773/04A patent/RU2217437C2/ru active
- 1998-12-22 SK SK960-2000A patent/SK286135B6/sk not_active IP Right Cessation
- 1998-12-22 BR BRPI9814499A patent/BRPI9814499B8/pt unknown
- 1998-12-22 NZ NZ505183A patent/NZ505183A/en not_active IP Right Cessation
- 1998-12-22 CN CNB98812582XA patent/CN1154655C/zh not_active Expired - Lifetime
- 1998-12-22 UA UA2000063810A patent/UA68366C2/uk unknown
- 1998-12-22 WO PCT/US1998/027282 patent/WO1999032510A1/fr not_active Ceased
- 1998-12-22 KR KR1020007006936A patent/KR100629548B1/ko not_active Expired - Lifetime
- 1998-12-22 ZA ZA9811801A patent/ZA9811801B/xx unknown
- 1998-12-22 AU AU19402/99A patent/AU747806B2/en not_active Ceased
- 1998-12-22 JP JP2000525447A patent/JP4275852B2/ja not_active Expired - Lifetime
- 1998-12-22 EP EP98964224A patent/EP1042359B1/fr not_active Expired - Lifetime
- 1998-12-23 AR ARP980106652A patent/AR014167A1/es active IP Right Grant
- 1998-12-23 UY UY25327A patent/UY25327A1/es unknown
1999
- 1999-02-10 TW TW087121390A patent/TW580502B/zh not_active IP Right Cessation
2000
- 2000-06-12 IL IL136742A patent/IL136742A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003245A patent/NO327080B1/no not_active IP Right Cessation
2006
- 2006-10-05 IL IL178471A patent/IL178471A0/en unknown

Also Published As

Publication number	Publication date
EP1042359A1 (fr)	2000-10-11
HK1029349A1 (en)	2001-03-30
CZ297281B6 (cs)	2006-10-11
HUP0100626A2 (hu)	2001-08-28
BRPI9814499B8 (pt)	2021-11-09
UA68366C2 (en)	2004-08-16
IL136742A (en)	2006-12-31
NO20003245L (no)	2000-08-23
US5965701A (en)	1999-10-12
IL136742A0 (en)	2001-06-14
NO20003245D0 (no)	2000-06-21
AU747806B2 (en)	2002-05-23
EE200000370A (et)	2001-10-15
NZ505183A (en)	2001-09-28
ZA9811801B (en)	1999-06-22
AR014167A1 (es)	2001-02-07
BR9814499B1 (pt)	2014-10-21
SK286135B6 (sk)	2008-04-07
ATE301670T1 (de)	2005-08-15
TR200001985T2 (tr)	2000-11-21
HUP0100626A3 (en)	2001-12-28
EP1042359B1 (fr)	2005-08-10
WO1999032510A1 (fr)	1999-07-01
HU227640B1 (en)	2011-10-28
JP2001526295A (ja)	2001-12-18
TW580502B (en)	2004-03-21
AU1940299A (en)	1999-07-12
KR20010033450A (ko)	2001-04-25
CZ20002382A3 (cs)	2000-12-13
DE69831176T2 (de)	2006-04-20
CR5936A (es)	2006-08-18
CA2315878C (fr)	2010-11-16
CA2315878A1 (fr)	1999-07-01
IL178471A0 (en)	2007-02-11
BRPI9814499B1 (pt)	2014-10-21
HRP20000415B1 (en)	2004-06-30
DE69831176D1 (de)	2005-09-15
WO1999032510A9 (fr)	1999-09-23
PL341308A1 (en)	2001-04-09
BR9814499A (pt)	2000-10-10
PT1042359E (pt)	2005-11-30
RU2217437C2 (ru)	2003-11-27
EE04440B1 (et)	2005-02-15
KR100629548B1 (ko)	2006-09-27
JP4275852B2 (ja)	2009-06-10
UY25327A1 (es)	2000-12-29
CN1154655C (zh)	2004-06-23
MY117542A (en)	2004-07-31
BRPI9814499A (pt)	2000-10-10
DK1042359T3 (da)	2005-11-28
ES2247735T3 (es)	2006-03-01
SK9602000A3 (en)	2001-01-18
CN1283201A (zh)	2001-02-07
HRP20000415A2 (en)	2000-12-31
PL195842B1 (pl)	2007-10-31

Publication	Publication Date	Title
NO327080B1 (no)	2009-04-20	Syntetisk opioidpeptidamid samt et farmasoytisk preparat
TWI423987B (zh)	2014-01-21	環肽ｃｘｃｒ４拮抗劑
US20100029575A1 (en)	2010-02-04	N-Oxides of Kappa Receptor Peptides
SK287880B6 (sk)	2012-02-03	Peptide LHRH-antagonists with improved solubility, pharmaceutical composition containing the peptides, method for the preparation of the peptides and their use and method for producing medicaments
JPH1053599A (ja)	1998-02-24	胃腸運動刺激活性を示す環状モチリン−様ポリペプチド
US5422341A (en)	1995-06-06	Motilin-like polypeptides with gastrointestinal motor stimulating activity
MXPA00006270A (en)	2001-07-03	Kappa receptor opioid peptides
HK1029349B (en)	2006-01-13	Kappa receptor opioid peptides
WO2019170919A1 (fr)	2019-09-12	Récepteur d'opioïde mu hybride et molécules de liaison de récepteur de neuropeptide ff, leurs procédés de préparation et d'applications dans un traitement thérapeutique
Hruby et al.	1995	Structure-function studies of peptide hormones: an overview
De Marco	2017	A Brief Survey on Recent Endomorphin-1 and Endomorphin-2 Analogues
PL226256B1 (pl)	2017-07-31	N-podstawione amidy cyklicznych ureidowych analogów dermorfiny, sposoby ich wytwarzania, zastosowanie i środek farmaceutyczny do leczenia i/lub łagodzenia stanów bólowych
RS51950B (sr)	2012-02-29	Ciklični peptidi antagonisti cxcr4

Legal Events

Date	Code	Title	Description
2013-07-29	MM1K	Lapsed by not paying the annual fees